Quick Takeaways
- James E. Flynn filed SCHEDULE 13D/A for Larimar Therapeutics, Inc. Common Stock, par value $0.01 per share (LRMR).
- Disclosed ownership: 34%.
- Date of event: 27 Feb 2026.
Quoteable Key Fact
"James E. Flynn disclosed 34% ownership in Larimar Therapeutics, Inc. Common Stock, par value $0.01 per share (LRMR) on 27 Feb 2026."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original Filing| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Deerfield Private Design Fund III, L.P. | 10% | 10,622,928 | 0 | 10,622,928 | /s/ Jonathan Isler | Jonathan Isler, Attorney-in-Fact | 0001603333 |
| Deerfield Healthcare Innovations Fund, L.P. | 7.9% | 8,153,107 | 0 | 8,153,107 | /s/ Jonathan Isler | Jonathan Isler, Attorney-in-Fact | 0001646981 |
| Deerfield Private Design Fund IV, L.P. | 10% | 10,622,957 | 0 | 10,622,957 | /s/ Jonathan Isler | Jonathan Isler, Attorney-in-Fact | 0001680307 |
| Deerfield Partners, L.P. | 6% | 6,207,982 | 0 | 6,207,982 | /s/ Jonathan Isler | Jonathan Isler, Attorney-in-Fact | 0001301041 |
| Deerfield Mgmt III, L.P. | 10% | 10,622,928 | 0 | 10,622,928 | /s/ Jonathan Isler | Jonathan Isler, Attorney-in-Fact | 0001610540 |
| Deerfield Mgmt HIF, L.P. | 7.9% | 8,153,107 | 0 | 8,153,107 | /s/ Jonathan Isler | Jonathan Isler, Attorney-in-Fact | 0001665736 |
| Deerfield Mgmt IV, L.P. | 10% | 10,622,957 | 0 | 10,622,957 | /s/ Jonathan Isler | Jonathan Isler, Attorney-in-Fact | 0001713467 |
| Deerfield Mgmt, L.P. | 6% | 6,207,982 | 0 | 6,207,982 | /s/ Jonathan Isler | Jonathan Isler, Attorney-in-Fact | 0001010823 |
| Deerfield Management Company, L.P. | 34% | 35,667,474 | 0 | 35,667,474 | /s/ Jonathan Isler | Jonathan Isler, Attorney-in-Fact | 0001009258 |
| James E. Flynn | 34% | 35,667,474 | 0 | 35,667,474 | /s/ Jonathan Isler | Jonathan Isler, Attorney-in-Fact | 0001352546 |